From the Research
The treatment for sclerosing mesenteritis should involve a combination of tamoxifen and prednisone as the first-line pharmacotherapy, with tamoxifen 10 mg twice daily and prednisone 40 mg daily, as this regimen has shown the most promising results in recent studies. The choice of treatment is based on the most recent and highest quality study available, which suggests that this combination is effective in reducing symptoms and improving outcomes in patients with sclerosing mesenteritis 1. Key points to consider in the treatment of sclerosing mesenteritis include:
- The use of tamoxifen and prednisone as the first-line treatment, due to their anti-fibrotic and anti-inflammatory properties
- The importance of monitoring treatment response through clinical symptoms, inflammatory markers, and follow-up imaging
- The potential need for surgical intervention in cases of severe obstructive symptoms, although this is generally avoided due to the risk of adhesions and disease progression
- The overall goal of treatment is to reduce inflammation, prevent fibrosis, and improve quality of life for patients with sclerosing mesenteritis. Some studies have also suggested the use of other medications, such as azathioprine, cyclophosphamide, or methotrexate, as steroid-sparing agents in long-term management 2, 3. However, the most recent and highest quality study available suggests that the combination of tamoxifen and prednisone is the most effective treatment regimen 1. It's also worth noting that asymptomatic patients do not require treatment, and that the treatment approach should be individualized based on the patient's specific symptoms and disease severity. Overall, the treatment of sclerosing mesenteritis requires a comprehensive approach that takes into account the patient's overall health, disease severity, and treatment response, with the goal of improving quality of life and reducing morbidity and mortality.